Evidence map›Paper›PMID 26343372›Full record

ArticleOncotarget2015

Bisphosphonate-induced differential modulation of immune cell function in gingiva and bone marrow in vivo: role in osteoclast-mediated NK cell activation.

Han-Ching Tseng, Keiichi Kanayama, Kawaljit Kaur, So-Hyun Park, Sil Park, Anna Kozlowska, Shuting Sun, Charles E McKenna, Ichiro Nishimura, Anahid Jewett

Erratum issuedOpen access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 88 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Immune Dysfunction in Medication-Related Osteonecrosis of the Jaw.International journal of molecular sciences · 2023
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Han-Ching TsengDivision of Oral Biology and Medicine, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, UCLA School of Dentistry, Los Angeles, CA, USA.
Keiichi KanayamaDivision of Advanced Prosthodontics, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, UCLA School of Dentistry, Los Angeles, CA, USA.
Kawaljit KaurDivision of Oral Biology and Medicine, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, UCLA School of Dentistry, Los Angeles, CA, USA.
So-Hyun ParkDivision of Oral Biology and Medicine, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, UCLA School of Dentistry, Los Angeles, CA, USA.
Sil ParkDivision of Oral Biology and Medicine, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, UCLA School of Dentistry, Los Angeles, CA, USA.
Anna KozlowskaDivision of Oral Biology and Medicine, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, UCLA School of Dentistry, Los Angeles, CA, USA.
Shuting SunDepartment of Chemistry, University of Southern California, Los Angeles, CA, USA.
Charles E McKennaDepartment of Chemistry, University of Southern California, Los Angeles, CA, USA.
Ichiro NishimuraDivision of Oral Biology and Medicine, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, UCLA School of Dentistry, Los Angeles, CA, USA.
Anahid JewettDivision of Oral Biology and Medicine, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, UCLA School of Dentistry, Los Angeles, CA, USA.
University of Southern California · USAsahi University · JPPoznan University of Medical Sciences · PL

Funding

Oral Mucosa Barrier and Bisphosphonate-related Osteonecrosis of the JawR01DE022552 · NIDCR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NISHIMURA, ICHIRO · 2012 to 2016
$2.2M
Molecular and cellular mechanism of ONJ related to osteoclast inhibitionR21DE023410 · NIDCR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MCKENNA, CHARLES E, NISHIMURA, ICHIRO · 2014 to 2015
$451k
EXTRAMURAL RESEARCH FACILITIES CONSTRUCTION PROJECTSC06RR014529 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PARK, NO-HEE · 1999 to 1999
–
NCRR NIH HHS C06 RR014529NIDCR NIH HHS R01 DE022552NIDCR NIH HHS R01DE022552NIDCR NIH HHS R21 DE023410NIDCR NIH HHS R21DE023410
6 · The paper itself

Abstract

The aim of this study is to establish osteoclasts as key immune effectors capable of activating the function of Natural Killer (NK) cells, and expanding their numbers, and to determine in vivo and in vitro effect of bisphosphonates (BPs) during NK cell interaction with osteoclasts and on systemic and local immune function. The profiles of 27 cytokines, chemokines and growth factors released from osteoclasts were found to be different from dendritic cells and M1 macrophages but resembling to untreated monocytes and M2 macrophages. Nitrogen-containing BPs Zoledronate (ZOL) and Alendronate (ALN), but not non-nitrogen-containing BPs Etidronate (ETI), triggered increased release of pro-inflammatory mediators from osteoclasts while all three BPs decreased pit formation by osteoclasts. ZOL and ALN mediated significant release of IL-6, TNF-` and IL-1β, whereas they inhibited IL-10 secretion by osteoclasts. Treatment of osteoclasts with ZOL inhibited NK cell mediated cytotoxicity whereas it induced significant secretion of cytokines and chemokines. NK cells lysed osteoclasts much more than their precursor cells monocytes, and this correlated with the decreased expression of MHC class I expression on osteoclasts. Intravenous injection of ZOL in mice induced pro-inflammatory microenvironment in bone marrow and demonstrated significant immune activation. By contrast, tooth extraction wound of gingival tissues exhibited profound immune suppressive microenvironment associated with dysregulated wound healing to the effect of ZOL which could potentially be responsible for the pathogenesis of Osteonecrosis of the Jaw (ONJ). Finally, based on the data obtained in this paper we demonstrate that osteoclasts can be used as targets for the expansion of NK cells with superior function for immunotherapy of cancer.

Indexed as

AlendronateAnimalsApoptosisBone MarrowCell CommunicationCell DifferentiationDiphosphonatesFemaleGingivaHumansImidazolesKiller Cells, NaturalMacrophagesMiceMice, Inbred C57BLMonocytesAlendronateDiphosphonatesImidazolesZoledronic AcidbisphosphonateetidronateImmune responseImmunityImmunology and Microbiology SectionNK cellosteoclastszoledronate

Identifiers

PMID26343372
PMCPMC4652983
OpenAlexW2102975924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.